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ABSTRACT
Hematopoietic stem cells comprise a prominent target for gene therapy aimed at treating various genetic and
acquired disorders. A number of limitations associated with hematopoietic cell transplantation can be circum-
vented by the use of cells stably modified by retroviral gene transfer. Oncoretroviral and lentiviral vectors offer
means for generating efficient and stable transgene expression. This review summarizes the state of the field to-
day in terms of vector development and clinical experimentation. In particular, concerns with the safety of ret-
roviral vectors intended for clinical gene transfer, applicability of preclinical data in directing clinical trial design,
and recent research aimed at resolving some of these issues are addressed. Finally, this review underlines the
specific advantages offered by lentiviral gene-transfer vectors for gene therapy in stem cells.
 2007 American Society for Blood and Marrow Transplantation
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Hematopoietic Cells as Targets for Gene Therapy
Hematopoietic cell transplantation (HCT) holds
promise for the treatment of many genetic and ac-
quired disorders [1]. A major limitation of this ap-
proach lies in the difficulty in finding suitable human
leukocyte antigen–matched donors [2]. Genetic modi-
fication of autologous hematopoietic cells to overcome
genetic deficiencies or to augment function offers an
alternative and reliable solution, avoiding the risks
and side effects associated with allotransplantation
[3-5]. Such modification requires efficient delivery
and stable expression of a therapeutic gene in hemato-
poietic cells with long-term repopulating capacity to
achieve enduring correction [6]. These criteria arewell met by integrating viral vectors, in particular, Mo-
loney murine leukemia virus (MoMLV)-derived on-
coretroviral vectors [7] and, more recently, human
immunodeficiency virus–derived lentiviral vectors [8].
Historically, progress in the field of gene therapy
has sometimes been impeded by lack of sufficient ad-
vancement in other fields. For example, the ability of
viruses to stably integrate their DNA into cells [9]
and the potential therapeutic applications of this new
tool [10] were recognized well before recombinant
DNA technology enabled the isolation and cloning
of specific genes in the 1970s [11]. In the early 1980s,
retroviral vectors were modified and sufficiently
improved to allow for the delivery of therapeutic
genes into almost any mammalian cell [12-14]. Their
safe and general use was made possible by the1407
1408 A. Neschadim et al.establishment of efficient packaging cell lines that al-
lowed production of high-titer, replication-defective,
helper-free viruses [7,15-17]. With the results of nu-
merous cell culture experiments and preclinical animal
studies in hand, many of which involved hematopoietic
stem cells (HSCs) and demonstrated success [18-26],
the field was primed for clinical studies.
Arguably, the first successful clinical trials with in-
tegrating vectors treated patients with severe combined
immunodeficiency (SCID) resulting from either an
X-linked defect in the interleukin-2 receptor g-chain
(IL-2Rg) (SCID-X1) or adenosine deaminase (ADA)
deficiency (SCID-ADA). Initial attempts to correct
SCID-ADA in patients were made in the mid-1990s
using retroviral gene-transfer vectors [27-30]. The
true success of these gene therapy trials is difficult to
measure, however, because the results were confounded
by concomitant administration of enzyme replacement
therapy in the form of polyethylene glycol (PEG)-
ADA. These clinical trials were followed by trials rely-
ing exclusively on gene therapy, especially in instances
in which enzyme replacement therapy was not avail-
able. In two separate trials published in the early
2000s, oncoretroviral vectors were used to deliver the
cDNA of the common IL-2Rg chain into HSCs by
transducing CD341 cells ex vivo, with transgene ex-
pression driven by the viral long-terminal repeat
(LTR) promoter. A French clinical trial treated 10 pa-
tients, 9 of whom developed a functional immune sys-
tem [31]. An analogous British trial also successfully
treated 10 patients [32]. Finally, an Italian trial success-
fully treated 8 patients with SCID-ADA by delivering
ADA cDNA with an oncoretroviral vector into
CD341 cells ex vivo [33,34]. Despite this success, 4 pa-
tients in the French SCID-X1 trial developed a T cell
lymphoblastic leukemia [35]. A possible explanation
for this finding is that ectopic expression of the thera-
peutic gene (the IL-2Rg chain) conferred apronounced
proliferative advantage to T cells migrating to lym-
phoid organs, which on the one hand contributes to
the improved engraftment and persistence of the T
cell progenitors and on the other hand probably in-
creases their susceptibility to malignant transforma-
tion through insertional mutagenesis [35]. These
trials have raised concerns about the safety of integrat-
ing viral vectors for use in gene therapy and have
prompted careful re-evaluation of their ability to trans-
form cells by integration.
Integration of vectors containing strong promoter
or enhancer elements near or into proto-oncogenes or
tumor-suppressor genes can significantly affect their
expression. This review discusses the lessons learned
from past clinical trials, shows how some parameters
are shaping the field of gene therapy today, and de-
scribes recent developments in vector safety and con-
siderations for the choice of novel genetic targets and
therapeutic vector design. Recent and ongoing clinical Ta
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Lentivirus-Mediated Gene Therapy with Hematopoietic Cell Transplantation 1409trials (see Table 1), including a recent first clinical trial
of a recombinant lentiviral vector [36,37], are also dis-
cussed in the appropriate context.
DISCUSSION
Development of Efficient and Safe Integrating Viral
Vectors for Gene Therapy
Successful and safe viral gene therapy aimed at
long-term correction requires an integrating vector
that conforms to a number of requirements. A success-
ful nonlytic vector for gene therapy should not be con-
tinually infectious; the primary transduction should be
terminal. Preventing infection of nontargeted cells is
necessary to avoid undesirable side effects, such as
germline transmission and inadvertent transmission
to other humans. This capacity was first achieved
with the initial generation of defective viruses, requir-
ing a supply of viral genes essential for infection and
replication, but not integration, in trans by a helper
cell line or from a separate plasmid [7,15]. The ability
to supply the viral envelope in trans led to the develop-
ment of multiple viral pseudotypes, expanding the
range of cells that can be transduced [38-40].
The nonlytic therapeutic viral vector also should
not replicate in target cells, ensuring that it does not
mobilize to infect other cells in the body or result in
germline transmission, and also to ensure that the vec-
tor is unable to recombine with or be rescued by other
viruses. Although the supply of viral genes essential for
replication solely in trans provided a partial solution,
this problem was largely solved by the development
of self-inactivating (SIN) vectors [8,41]. SIN vectors
contain a deletion in the promoter and enhancer ele-
ments of their 30 LTR that is transferred to the 50
LTR during reverse transcription and integration
[41], as shown in Figure 1. Thus, the integrated provi-
rus then contains LTRs that are largely transcription-
ally inactive [42] and whose activity is not upregulated
during infection of the cell with other retroviruses.
The development of SIN vectors further revolu-
tionized the field at the time by fulfilling a number of
other expectations from a therapeutic perspective.
SIN vectors enable the expression of therapeutic genes
under the control of any promoter/enhancer elements
(including broadly effective promoters, tissue-specific
promoters, and inducible promoters). They also bring
a new level of safety, because elimination of the strong
endogenous promoter activity of the viral LTRs signif-
icantly reduces the ability of integrating retroviral vec-
tors to activate surrounding cellular proto-oncogenes
by insertional mutagenesis [43]. Finally, partial dele-
tion of LTR sequences dramatically reduces the odds
of generating replication-competent recombinants
during viral production [41]. This vector improvement
still merits careful consideration of therapeutic genes
and/or promoters to drive transgene expression, as ex-emplified in the partial failure of the French SCID-X1
clinical trial, albeit using a different retroviral gene de-
livery system. For gene therapy in HSCs that will give
rise to all hematopoietic lineages, particular care also
should be taken when choosing promoters to drive
equivalent transgene expression in the different line-
ages. Care also should be exercised when choosing
therapeutic genes that could endow cells with an unfair
proliferative or survival advantage, which conceivably
could facilitate malignant transformation. Generally,
the introduction of transgenes involved in signaling
(e.g., receptors, kinases, adapters) should be avoided,
unless their signaling capacity is removed. Various as-
says can be used to address the potential of the deliv-
ered genes to affect the proliferation or survival of
transduced cells. In vitro, this could be evaluated
through measurements of cellular proliferation or
long-term growth rates, or by quantification of compe-
tition with nontransduced cells in culture [43]. Effects
on survival can be addressed by measurements of nor-
mal, receptor-induced, or drug-induced apoptosis in
culture. In vivo, competitive repopulation assays [44]
or spontaneous oncogenesis models could be used to
address these issues [45]. Finally, more sophisticated
methods involving expression profiling after transgene
delivery by either microarray or proteomic approaches
could be used.
The ideal vector for delivery of genes into HSCs
also should be able to transduce nondividing cells.
This particular requirement makes transduction of
HSCs difficult with most oncoretroviral vectors [46],
requiring extensive temporal and factor manipulation
of HSCs ex vivo to induce cell division, which ulti-
mately affects their differentiation and repopulation
capacities [47]. Development of HIV-1–derived re-
combinant lentiviral SIN vectors, stripped of nearly
all wild-type HIV-1 viral proteins, has made the trans-
duction of nondividing cells possible without the need
for mitosis, diminishing the need to extensively acti-
vate target cells, which can affect their phenotype
and differentiation [8,48]. In particular, infection of
nondividing cells by recombinant lentiviral vectors
and vector integration has been enhanced by the inclu-
sion of the short central polypurine tract (cPPT) se-
quence from the pol of HIV-1, which facilitates
nuclear translocation of the viral transcripts in the
cell [49]. Lack of interaction of recombinant lentiviral
vectors with wild-type HIV-1 in infected cells has
ameliorated other concerns associated with their use
[50]; however, deliberate retention of such interactions
also has been successfully exploited to enhance anHIV
treatment strategy, whereby retention of the native
LTR in the therapeutic vector results in preferential
up-regulation of transgene expression in cells with
active HIV infection [36,37]. An HIV-1–derived
recombinant lentivirus is ideally suited for this
study, which is also the first clinical trial to use
1410 A. Neschadim et al.Figure 1. Self-inactivating retroviral gene transfer vector design. A, Virus-specific tRNA binds to the primer binding site
(PBS). B, The viral RNA is reverse transcribed by the viral reverse transcriptase (RT) using a cellular tRNA as a primer, and
the newly formedDNA strand is synthesized toward the 50 LTR complementary to the viral sequence. C, The viral RNAR
and U5 sequences are removed by RNase H activity of RT, which digests the RNA strand in the double-stranded RNA-
DNA hybridmolecules. D, The resulting short DNA segment then jumps to the remaining R sequence on the viral RNA at
the 30 LTR. E, The short DNA segment is further extended to synthesize a DNA segment complementary to the full length
of the remaining viral RNA. F, Most of the resulting RNA in the RNA-DNA hybrid is digested. G, The remaining hybrid-
ized RNA primes the synthesis of the second DNA strand. A segment is synthesized complementary to the 30 LTR and the
viral tRNA, which now includes the PBS sequence and the deletion in the U3 region of 30 LTR. H, The remaining RNA is
then digested. I, The short DNA segment on the second strand jumps to the complementary PBS site. J, Completion of
DNA synthesis on both strands results in the double-stranded DNA provirus. The 30 LTR deletion in the U3 region is
transferred to the 50 LTR of the newly made provirus. The 50 LTR is now inactive and is incapable of driving transcription
of the viral genome. The delivered transgene is expressed from a separate internal promoter.lentiviral gene-transfer vectors. An overview of recent
lentivirus-based clinical trials aimed at HIV treatment
is available elsewhere [51].
Recently, studies of retroviral integration sites have
suggested that lentiviral vectors are safer than oncore-
troviral vectors for delivery of therapeutic genes in vitroand in vivo, as well as in applications involving HSCs
[52-54]. In particular, oncoretroviral vectors tend to in-
tegrate preferentially into promoter-proximal regions
and do so in a recurrent fashion, whereas lentiviral
vectors appear to use a more random mode of integra-
tion, mainly inserting into open chromatin [52].
Lentivirus-Mediated Gene Therapy with Hematopoietic Cell Transplantation 1411Pyrosequencing (currently the fastest real-time ‘‘se-
quencing by synthesis’’ method) was recently used in
a study in a high-throughput analysis to map more
than 40,000 unique HIV integration sites, allowing
the elucidation of novel associations between viral inte-
gration modes and frequencies and various genomic
features [55]. The propensity of retroviral vectors to in-
tegrate into active genes further underscores the im-
portance of careful dosing of the viral loads used for
target cell transductions [56], with the current trend
toward using low multiplicity of infection and the de-
velopment of techniques for selective enrichment of
transduced cells to ensure maintenance of therapeutic
efficacy [57-60]. Because the retroviral integrase
largely determines the specificity of integration, future
research into integration targeting aimed at engineer-
ing the viral integrase accordingly may help ameliorate
some of the current safety concerns with insertional
mutagenesis [61-63].
As safe as lentiviral vectors have proved so far,
approved clinical protocols for gene therapy based on
integrating viral vectors are still largely restricted to
patients with limited therapeutic alternatives. Our lab-
oratory and others are working on developing the next
generation of safer therapeutic lentiviral vectors. In ad-
dition to the therapeutic gene, these vectors would in-
corporate a molecular ‘‘safety switch’’ to ensure that
any malignancy resulting from cellular transformation
induced by insertional mutagenesis of the therapeutic
vector or other causes can be selectively and safely re-
moved. In this context, one approach involves the de-
livery of a suicide gene along with a therapeutic gene
into target cells. Expression of a suitable suicide gene
in target cells gives these cells the ability to convert
a normally nontoxic prodrug into a cytotoxic antime-
tabolite, resulting in the selective elimination of these
cells by apoptosis on systemic prodrug administration
[64]. A prototypic enzyme/prodrug combination
adopted from in vivo selection strategies and in wide-
spread use today is the herpes simplex virus thymidine
kinase (HSV-tk) enzyme, along with ganciclovir
(GCV) or acyclovir (ACV) as prodrugs [65]. But this
system has numerous problems, including poor pro-
drug activation kinetics by HSV-tk [66] and the fact
that HSV-tk, being a heterologous protein, is capable
of generating immune responses of its own [67]. An-
other suicide gene/prodrug system recently developed
in our laboratory [68] involves the introduction of
a highly catalytically improved variant of human thy-
midylate monophosphate kinase (tmpk) that catalyzes
the robust activation of the prodrug zidovudine
(AZT) into its active cytotoxic form [69]. On adminis-
tration of low, subtoxic amounts of AZT, transduced
cells are selectively and rapidly eliminated in vivo
[68]. As a secondary strategy, our laboratory has also
recently demonstrated that cells transduced with
a therapeutic vector encoding a cell surface–expressedmarker (human CD25 in this case) can be targeted and
killed selectively in vivo with an antibody conjugated
to an immunotoxin [70]. These strategies are illus-
trated in Figure 2. Thus, incorporation of such suicide
genes into therapeutic vectors may prove to be a neces-
sary and universal step toward safer gene therapy for
various applications.
Design of Viral Vectors Aimed at Gene Therapy
with Autologous HSCs
Numerous factors need to be considered in the es-
tablishment of successful genetic therapies involving
the use of autologous HSCs. The development of
unwanted immune responses against vectors and/or
delivered transgene products is a major concern. In
1999, an early clinical trial of an adenoviral vector
for treating ornithine transcarbamylase deficiency re-
sulted in the death of an 18-year-old patient because
of a severe immune response against the vector [71].
Fortunately, retroviral vector platforms have been
stripped of most endogenous viral genes [7,35] and
are expected to elicit limited activation of the immune
system. Nevertheless, concerns regarding the develop-
ment of immune responses against the vector have not
yet been fully addressed. Recently, analysis of results
from a set of clinical trials aimed at controlling graft-
versus-host disease (GVHD) in allogeneic bone mar-
row transplant recipients undergoing chemotherapy
found that the desired clinical efficiency was not
achieved for various reasons [67]. Retrospective analy-
sis demonstrated that the in vivo persistence of trans-
duced cells was limited, likely because of the immune
responses against the foreign transgene that developed
in some patients [67]. A similar outcome also was ob-
served in recent preclinical nonhuman primate studies
involving ectopic overexpression of autologous eryth-
ropoietin, which led to the development of autoimmu-
nity [72,73]. The results of these studies point to the
need for careful examination of the potential immuno-
genicity of therapeutic vectors and transgene products
in human subjects before approval of clinical proto-
cols, and suggest that for most gene therapy applica-
tions, a human-origin transgene or a close variant
should be used.
Large numbers of HSCs are needed to achieve
successful engraftment at high proportions [74,75];
however, transducing a useful number of HSCs with
long-term repopulating capacity resident in CD341
populations or bone marrow (BM) is challenging. This
limitation can be overcome by delivering genes that
confer a proliferative or survival advantage to the
transplanted cells, to ensure their engraftment and
long-term persistence; however, this advantage may
potentially accelerate the development of hematologic
malignancies and/or result in oligoclonal expansion of
transplanted polyclonal cell populations, as demon-
strated in a French clinical trial involving SCID-X1
1412 A. Neschadim et al.Figure 2. Strategies aimed at establishing control over the fate of transduced cells. In a given therapeutic setting, trans-
planted cells transduced with a viral vector harboring a safety element can be selectively cleared from the patient’s circu-
lation by administration of normally nontoxic pharmacological agents. Transduced cells expressing amodified tmpk suicide
gene [68] and/or a CD25molecule [70] can be selectively eliminated by administration of an AZTprodrug or an anti-CD25
antibody conjugated to saporin toxin, respectively. Alternatively, cells transduced with a chimeric receptor with pharma-
cologically controlled signalling can be selectively expanded ex vivo or in vivo by drug administration [77]. Cells transduced
with the chimeric kinase insert domain–containing receptor developed in our laboratory [80] can preferentially expand in
response to the administration of a chemical inducer of dimerization molecule, AP20187, which induces the activation of
anti-apoptotic signaling.patients [35].Our laboratory and others have been pur-
suing the development of a therapeutically suitable so-
lution to this problem. Ex vivo or in vivo expansion of
limited numbers of autologous HSCs can be achieved
by introduction of a drug-induced positive selection
element that allows for controlled enhancement of
proliferation and/or survival of transduced cells during
culture, as shown in Figure 2 [76-79]. One such
approach developed in our laboratory involves the
transduction of TF1 cells with a pharmacologically
regulated kinase insert domain (KDR)-containing chi-
meric receptor [80]. This receptor contained binding
domains for the chemical inducer of dimerization
(CID) molecule (AP20187). Binding of AP20187 to
the AP20187-binding domain results in dimerization
of the receptor and cross-linking of the signaling
KDR domains. The KDR signaling cascade, activated
in response to AP20187 drug treatment, ultimately
protects transduced cells from apoptosis. Our labora-
tory is currently developing strategies for evaluating
the utility of other signaling domains in the context
of selectively expanding transduced HSCs.Targets for Genetic Modification of Autologous
HSCs
The choice of disorders for gene therapy is also
influenced by the nature of the delivered gene. It should
be emphasized that current vectors designed for the de-
livery of therapeutic genes into HSCs are designed to
achieve gene augmentation rather than gene correc-
tion. Endogenous gene expression from the defective
alleles and their function remain largely unaffected
after viral delivery of a corrected gene, unless a domi-
nant-negative effect is engineered. Yet for some dis-
orders, restoration of wild-type function, even in the
face of this, may suffice to effect correction. Gene
therapy for Fabry disease, as fully developed in our lab-
oratory, is a good example of how gene augmentation
can restore function and correct the disease condition.
Reconstitution of some level of the activity of a-galac-
tosidase (the defective enzyme in Fabry disease)
through lentiviral delivery of its cDNA into HSCs
can achieve significant systemic correction of this met-
abolic disorder in fabry mice [81]. Nonetheless, many
disorders may require correction of the endogenous
Lentivirus-Mediated Gene Therapy with Hematopoietic Cell Transplantation 1413genetic defect to achieve full therapeutic efficacy. Re-
cent developments in gene knockdown technologies
may provide the necessary tools for the development
of therapies for such disorders. Advances in specific
gene knockdown using targeted shRNA or microRNA
methodologies enable the design of bi-cistronic vectors
not only to deliver a corrected version of the gene, but
also to selectively suppress expression of the endoge-
nous defective variant [82-84]. Thus, vectors that
achieve an outcome closer to actual gene correction
may now be established, broadening the spectrum of
conditions that can be treated by gene therapy with
HSCs. Of particular note, manipulation of genes of
the immune system, such as potential replacement of
major histocompatibility complex (MHC) molecules
on transplanted cells [84], holds great promise for the
use of gene therapy vectors in transplantation.
Results from an increasing number of studies now
suggest that transplantation of HSCs or embryonic
stem (ES) cells on their own may not be sufficient to
treat every condition and may not always be safe.
This is well exemplified in recent studies involving
ES cells that have found teratoma formation in the
brain and heart [85-87]. It is becoming clear that ge-
netic modification of ES cells may be necessary to
overcome many of the current difficulties associated
with their use, and new research is being focused in
that direction. Although a more directed approach
aimed at modifying specific genes would be desirable,
the use of suicide gene therapy as a gross control
against teratoma development has been suggested
[68,88].
Future Developments in Gene Therapy Vectors
Any disorder chosen for gene therapy should be
thoroughly investigated in preclinical models of dis-
ease. That said, success in preclinical models (espe-
cially rodent models) often does not predict success
in the clinic. Thus, an in-depth understanding of the
biochemistry and pathobiology of the disease often is
needed before an attempt can be made to correct it
by gene therapy. However, the field of gene therapy
is now at a stage where it is much easier to design a vec-
tor for the correction of a particular disorder than to
engineer it to be sufficiently safe, efficient, and specific.
Genetic engineering of HSCs remains one of the most
powerful approaches to achieving functional and tem-
poral correction. But the strength of this approach,
stemming from the great proliferative and differentia-
tive capacities of HSCs, is also its greatest weakness,
making genetic modification of these cells an under-
taking that must be approached with caution. Conse-
quently, much of the future research should be
directed toward improving the safety of therapeutic vi-
ral vectors and developing means for tissue-specific
expression that can be regulated; for example, somecurrent research involves the development of vectors
that contain promoters that are tissue-specific and/or
can be regulated to achieve specific correction [89-
92]. Further inclusion of various chromatin insulator
elements into integrating viral vectors may minimize
the effects of surrounding genes on transcription
[93]. Some research is being directed toward the devel-
opment of stable episomal nonviral vectors [94,95].
Finally, although the search for the ideal vector con-
tinues, only the outcomes of the many preclinical
and clinical studies will determine what this vector
will look like in the near future.
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